Our top pick for
Novus Therapeutics, Inc is a biotechnology business based in the US. Novus Therapeutics shares (NVUS) are listed on the NASDAQ and all prices are listed in US Dollars. Novus Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of USD$28.8 million.
|Latest market close||USD$20.03|
|52-week range||USD$4.5 - USD$26.44|
|50-day moving average||USD$20.8521|
|200-day moving average||USD$13.6127|
|Wall St. target price||USD$23.37|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.702|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||37.19%|
|1 month (2020-12-16)||9.16%|
|3 months (2020-10-15)||20.66%|
|6 months (2020-07-15)||4,082.50%|
|1 year (2020-01-15)||2,691.64%|
|2 years (2019-01-15)||765.23%|
|3 years (2018-01-12)||438.89%|
|5 years (2016-01-15)||275.80%|
Valuing Novus Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novus Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novus Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Novus Therapeutics shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novus Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novus Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||USD$0|
|Return on assets TTM||-7.29%|
|Return on equity TTM||-21.07%|
|Market capitalisation||USD$28.8 million|
TTM: trailing 12 months
There are currently 115,315 Novus Therapeutics shares held short by investors – that's known as Novus Therapeutics's "short interest". This figure is 299.1% up from 28,893 last month.
There are a few different ways that this level of interest in shorting Novus Therapeutics shares can be evaluated.
Novus Therapeutics's "short interest ratio" (SIR) is the quantity of Novus Therapeutics shares currently shorted divided by the average quantity of Novus Therapeutics shares traded daily (recently around 34733.43373494). Novus Therapeutics's SIR currently stands at 3.32. In other words for every 100,000 Novus Therapeutics shares traded daily on the market, roughly 3320 shares are currently held short.
However Novus Therapeutics's short interest can also be evaluated against the total number of Novus Therapeutics shares, or, against the total number of tradable Novus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novus Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Novus Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1089% of the tradable shares (for every 100,000 tradable Novus Therapeutics shares, roughly 109 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novus Therapeutics.
Find out more about how you can short Novus Therapeutics stock.
We're not expecting Novus Therapeutics to pay a dividend over the next 12 months.
Novus Therapeutics's shares were split on a 1:18 basis on 5 October 2020. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novus Therapeutics shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Novus Therapeutics shares which in turn could have impacted Novus Therapeutics's share price.
Over the last 12 months, Novus Therapeutics's shares have ranged in value from as little as $4.5 up to $26.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novus Therapeutics's is 2.3075. This would suggest that Novus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.